自我管理的自身免疫注射劑的全球市場（到 2028 年）

Self-Administered Autoimmune Injectables to 2028

出版日期: 2023年01月04日 | 出版商:

Greystone Research Associates | 英文 160 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

由於廣泛影響患者健康和福祉的疾病和適應症數量不斷增加，治療性免疫調節給藥正成為越來越重要的醫療選擇。然而，為了從人類和收入的角度釋放這類療法的全部價值，開發人員必須應對藥物儲存和給藥的固有挑戰，並從靜脈給藥途徑過渡到注射給藥途徑。用於慢性疾病（如自身免疫）的抗體藥物通常會重新配製、重新包裝、重新貼上註射劑的標籤，並在上市兩到三年後重新上市。這是由於越來越大的經濟壓力和不需要門診輸液的患者希望自行注射的願望。

本報告分析了全球自我管理的自身免疫注射劑市場，概述了產品、當前市場推出/開發狀態、主要市場驅動因素/制約因素、主要參與者概況以及市場規模/市場份額（到 2028 年） )、資本交易和技術/商業聯盟的近期趨勢、技術、設計和市場發展問題，以及主要市場背景（經濟、技術和監管因素）。我們將收集信息並發送給您。

內容

執行摘要
自行進行自身免疫注射
執行摘要
市場動態
競爭格局
醫藥供應鏈活動
產品設計和實現因素
易於使用
患者依從性
給藥頻率
人體工程學/人體工程學
售前和售後設備的演變
自我管理實現裝置
設備選擇：穩定性和材料問題
預裝注射器
自動注射器
Physioject（Becton Dickinson）
感應筆
Enbrel SureClick（安進）
SmartJect（PA 諮詢/Centocor）
Pegasys Proclick（基因泰克/羅氏）
專用自動注射器
注射筆
雙腔筆
新設備
自行給藥/治療性自身免疫藥物
Actemra（托珠單抗）
Benlysta（葛蘭素史克/人類基因組科學）
倍他龍
Cosentyx
Extavia
伊路米婭
齊尼雷特
腫瘤壞死因子
安捷維他
貝尼帕利語
Enbrel（依那西普）
哈利馬托茲
赫菲亞
辛波尼（戈利木單抗）
強直性脊柱炎
克羅恩病
成人類風濕性關節炎
幼年特發性關節炎
多發性硬化症
銀屑病關節炎
潰瘍性結腸炎
市場因素
監管因素
臨床試驗方案和終點
聯盟和夥伴關係
公司簡介

簡介目錄

Product Code: SAK955V

“Self-Administered Autoimmune Injectables to 2028” is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this growing segment of the drug delivery sector. The report has been designed and developed to provide pharmaceutical company decision makers, drug developers and formulators, drug device designers, and industry strategists with a detailed understanding of the expanding impact of next generation injection devices on pharmaceutical strategies and healthcare treatment protocols. Provider organization business managers, healthcare administrators and investors will also benefit from this publication.

Converging Factors Driving Self-administered Autoimmune Care

The administration of therapeutic immune modulators is becoming an increasingly important healthcare treatment option for a growing number of diseases and indications having broad implications for patient health and well-being. But to fully exploit the value of this class of therapeutics in both human and commercial terms, developers must successfully navigate the inherent limitations of drug storage and administration, moving away from infusion and toward injection as a route of administration. Antibody drug products indicated for chronic conditions such as autoimmunity are often re-formulated, re-packaged and re-labeled into injectable form and re-introduced two to three years post-market launch to address the growing economic pressure and patient desire to avoid the need for out-patient infusion in favor of self-injection. This report describes key factors in the trend toward patient enablement and self-administration.

What You Will Learn:

What approved drugs indicated for autoimmune conditions are marketed for self-administration, what is the as-supplied packaging, and who markets them?

What are the major factors driving the migration of infusible drugs for treating autoimmunity to formulations that can be packaged and administered subcutaneously?

What is the size of the market for self-administered autoimmune injectable drugs today, who are the market share leaders, and what will the market share be in 2028?

How important are drug developer-device manufacturer relationships and what are the key alliances in the industry?

What are the essential design factors, technologies and market development issues for devices that can deliver injectable autoimmune drugs subcutaneously?